Join
Live feed
·
INSIDERFilingvia Quantisnow
CytomX Therapeutics Inc. logo

Chief Financial Officer Ogden Christopher sold $5,122 worth of shares (8,551 units at $0.60), decreasing direct ownership by 4% to 201,026 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTMX (CytomX Therapeutics Inc.) and more on Quantisnow.